Coeptis Therapeutics Holdings's EBIT per Share for the
three
months ended in Dec. 2025 was $-0.22.
Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 was $-3.06.
During the past 3 years, the average EBIT per Share Growth Rate was 59.90% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 19.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Coeptis Therapeutics Holdings's EBIT per Share or its related term are showing as below:
COEP'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -36.6 Med: 27.6 Max: 59.9
Current: 59.9
During the past 6 years, the highest 3-Year average EBIT per Share Growth Rate of Coeptis Therapeutics Holdings was 59.90% per year. The lowest was -36.60% per year. And the median was 27.60% per year.
COEP's 3-Year EBIT Growth Rate is not ranked
in the Biotechnology industry.
Industry Median: 15.35
vs COEP: 59.90
Coeptis Therapeutics Holdings (NAS:COEP) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Coeptis Therapeutics Holdings EBIT per Share Related Terms
Coeptis Therapeutics Holdings EBIT per Share Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Coeptis Therapeutics Holdings EBIT per Share Chart
EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.06
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Coeptis Therapeutics Holdings (COEP) has a EBIT per Share of $-3.06 as of Dec. 2025. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Coeptis Therapeutics Holdings and its competitors.
Is Coeptis Therapeutics Holdings' EBIT per Share too high?
Coeptis Therapeutics Holdings' current EBIT per Share is $-3.06. Overall, Coeptis Therapeutics Holdings has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Coeptis Therapeutics Holdings' EBIT per Share compare to ANIX and COYA?
Coeptis Therapeutics Holdings' EBIT per Share of $-3.06 can be compared against companies in the Biotechnology industry. The industry median EBIT per Share is 15.35. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Biotechnology company?
The median EBIT per Share among Biotechnology companies is 15.35, based on 1,172 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Coeptis Therapeutics Holdings and its competitors. For the Biotechnology industry, the median EBIT per Share is 15.35 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Coeptis Therapeutics Holdings's current EBIT per Share is $-3.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Coeptis Therapeutics Holdings stock overvalued right now?
Coeptis Therapeutics Holdings (COEP) has a current EBIT per Share of $-3.06. The current EBIT per Share is $-3.06. Coeptis Therapeutics Holdings' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Coeptis Therapeutics Holdings (COEP), the current EBIT per Share is $-3.06 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Coeptis Therapeutics Holdings Business Description
Coeptis Therapeutics Holdings Inc is a biopharmaceutical and technology company. The biopharmaceutical division focuses on developing cell therapy platforms for cancer, autoimmune, and infectious diseases. Coeptis aims to advance treatment paradigms and improve patient outcomes through its research and development efforts. The technology division focuses on enhancing operational capabilities through technologies. This division features AI-powered marketing software and robotic process automation tools designed to optimize business processes and improve overall efficiency. It derives the majority of the revenue from the Technology segment.
12GF Score
Get the complete analysis for COEP
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
COEP has been successfully added to your 
